{"organizations": [], "uuid": "713fbf1ef8b440b2ae7dd79ca84c9ab9a3891ffb", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180214.html", "section_title": "Archive News &amp; Video for Wednesday, 14 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-agios-reports-qtrly-loss-per-share/brief-agios-reports-qtrly-loss-per-share-1-81-idUSASB0C5MY", "country": "US", "domain_rank": 408, "title": "BRIEF-Agios Reports Qtrly Loss Per Share $1.81", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.028, "site_type": "news", "published": "2018-02-14T20:06:00.000+02:00", "replies_count": 0, "uuid": "713fbf1ef8b440b2ae7dd79ca84c9ab9a3891ffb"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-agios-reports-qtrly-loss-per-share/brief-agios-reports-qtrly-loss-per-share-1-81-idUSASB0C5MY", "ord_in_thread": 0, "title": "BRIEF-Agios Reports Qtrly Loss Per Share $1.81", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "agios pharmaceuticals inc", "sentiment": "negative"}, {"name": "agios pharmaceuticals", "sentiment": "none"}, {"name": "thomson reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 14 (Reuters) - Agios Pharmaceuticals Inc:\n* AGIOS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS\n* QTRLY LOSS PER SHARE $1.81 * QTRLY TOTAL REVENUE $9.8 MILLION VERSUS $22.6 MILLION * Q4 EARNINGS PER SHARE VIEW $-1.66 -- THOMSON REUTERS I/B/E/S\n* AGIOS PHARMACEUTICALS - SEES CASH, CASH EQUIVALENTS AS OF DEC 31, 2017 ENABLING CO TO FUND EXPENSES, CAPEX REQUIREMENTS THROUGH AT LEAST END OF 2020 Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-14T20:06:00.000+02:00", "crawled": "2018-02-15T20:38:09.004+02:00", "highlightTitle": ""}